Vulcan Two Group complete 3 acquisitions, Placing to raise £40 million and Readmission of the Enlarged Share Capital to trading on AIM
March 2026
Vulcan Two Group plc is an LSE AIM listed investment company that was established to acquire companies or businesses that the Directors believe have the potential to generate Shareholder value.
The Directors will focus on acquiring companies in the ePharmacy market and will initially focus on businesses operating substantially in the UK. The company wants to “lead the consolidation of the private prescription sector – one of the fastest growing and most profitable sectors of the UK pharmacy market”.
The Group’s two Executive Directors, Michael Kraftman and Brendan O’Brien, have leading experience in the eCommerce healthcare sector, having built Vision Direct, one of Europe’s leading online contact lens suppliers, between 2009 and 2021.
Acquisitions, Placing and Readmission of the Enlarged Share Capital to trading on AIM
Following shareholder approval for the acquisitions of CloudRx Holdings Limited, Hyperdrug Pharmaceuticals Ltd and Webmed Pharmacy Ltd at the General Meeting as announced on 17th March 2026, first day dealings commenced on 19th March 2026 by way of a Placing of 20,000,000 Placing Shares at 200 pence per Placing Share to raise gross proceeds of £40 million and Readmission of the Enlarged Share Capital to trading on AIM.
Having helped Vulcan Two when they floated on AIM in September 2025, the Perivan shareholder communications team was delighted to work with Canaccord Genuity who acted as Nominated Adviser and Broker to the Company on the 153-page admission document which was successfully produced and published on 27th February 2026.
For further information, click here.
Perivan is the market-leading provider of New Issue and IPO admission document production, having maintained its leadership position for six consecutive years.